Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: A pharmacological strategy for treating stimulant abuse

Synapse

Volumn 35, Issue 3, 2000, Pages 222-227

  Rothman, Richard B ^a   Partilla, John S ^a   Baumann, Michael H ^a   Dersch, Christina M ^a   Carroll, F Ivy ^b   Rice, Kenner C ^c  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b RTI INTERNATIONAL   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Dopamine; MDMA; Methamphetamine; Norepinephrine; Serotonin; Transporters

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE; INDATRALINE; METHAMPHETAMINE; NORADRENALIN; SEROTONIN;

ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; DOPAMINE RELEASE; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; INDANS; METHAMPHETAMINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NOREPINEPHRINE; RATS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE-RELATED DISORDERS;

EID: 0033984392     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(20000301)35:3<222::AID-SYN7>3.0.CO;2-K     Document Type: Article

References (12)

1. Anonymous. 1995. Increasing morbidity and mortality associated with abuse of methamphetamine - United States, 1991-1994. MMWR Morb Mortal Wkly Rep 44:882-386.
2. Baumann MH, Char GU, de Costa BR, Rice KC, Rothman RB. 1994. GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat. J Pharmacol Exp Ther 271:1216-1222.
3. DEA. 1998. Drug Enforcement Administration Publication DEA-98036. The National Narcotics Intelligence Consumers Committee (NNICC) Report, 1997. Washington, DC: DEA, Intelligence Division.
4. Glowa JR, Fantegrossi WE, Lewis DB, Matecka D, Rice KC, Rothman RB. 1996. Sustained decrease in cocaine-maintained responding in rhesus monkeys with 1-[2-]Bis(4-fluorophenyl)methoxy[ethyl]-4-(3-hydroxy-3-phenylprop yl)piperaziny] decanoate, a long-acting ester derivative of GBR 12909. J Med Chem 39:4689-4691.
5. Gundlah C, Martin KF, Heal DJ, Auerbach SB. 1997. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther 283:581-591.
6. Hyttel J, Larsen JJ. 1985. Neurochemical profile of Lu 19-005, a potent inhibitor of uptake of dopamine, noradrenaline, and serotonin. J Neurochem 44:1615-1622.
7. Ricaurte GA, McCann UD. 1992. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann NY Acad Sci 648:371-382.
8. Rothman RB, Lewis B, Dersch CM, Xu H, Radesca L, de Costa BR, Rice KC, Kilburn RB, Akunne HC, Pert A. 1993. Identification of a GBR12935 homolog, LR1111, which is over 4000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters. Synapse 14:34-39.
9. Rudnick G, Clark J. 1993. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters (Review). Biochim Biophys Acta 1144:249-263.
10. Seiden LS, Sabol KE, Ricaurte GA. 1993. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33:639-677.
11. 11C]WIN35,428 PET scans. Synapse 32:44-50.
12. Wise RA. 1996. Neurobiology of addiction. Curr Opin Neurobiol 6:243-251.